Marex Group plc, a financial services platform provider company, provides liquidity, market access, and infrastructure services to clients in the energy, commodities, and financial markets. It operates through Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions segments. The company offers execution and clearing services in metals, agricultural products, energy and financial futures and options; liquidity and execution services for financial securities through trading desks that cover products, including foreign exchange, equities, fixed income, and others. It also operates as an agent to trade in OTC energy products using knowledge of the energy sector and relationships with clients for oil, power and gas, and shipping and freight products; and provides market-making services across commodities markets, such as metals, agricultural products, and energy markets. In addition, the company offers OTC traded hedging and customized OTC derivatives solutions; and risk management solutions across commodity markets comprising agriculture, metals, energy, and currency markets for trading houses, producers and consumers, and banks and distributors. Further, it engages in the structured notes business, which allows investors to build structured notes across asset classes, including commodities, equities, foreign exchange, and fixed-income products for private banks, independent asset managers, pension funds, and corporates. Additionally, it offers technology platforms, including Neon, a trading, risk, and data platform; and Agile, a commodity broking platform. The company operates in the United Kingdom, the United States, and internationally. Marex Group plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Marex Group plc

In a report released today, Benjamin Budish from Barclays maintained a Buy rating on Marex Group plc, with a price target of $49.00. According to T...

Barclays Sticks to Their Buy Rating for Marex Group plc (MRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SOPHiA GENETICS (SOPH – Research Report) and Immunee...

Market Cap	$2.80B	P/E Ratio	10.40
52W High	$49.34	52W Low	$27.91
Div Yield	60.0%	Payout Ratio	N/A
EPS Growth 3Y	87.7%	52W Position	56.1%
Overall Score	57	Value Score	--
Quality Score	52	Technical Score	63

EPS Current Est	$3.84	EPS Next Est	$4.35
EPS Growth Est	+13.3%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRX	$39.94	+2.02%	717.29K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRX	$39.94	+2.0%	717.29K
3
4
5
6

MRX

MRX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Marex Group plc Data in Excel

Get Marex Group plc Data in Excel